The Study
15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss
This study was done on mice, not people, and only tested a few animals. It shows that when mice got a certain drug and another chemical, their muscles seemed to heal better after injury—but that doesn’t mean it will work the same way in humans.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
When mice lose weight with a drug like Ozempic, their muscles get weaker when they get hurt — but a second drug can fix that.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 518 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this suggests people on weight-loss drugs like semaglutide might recover muscle strength faster after injury or surgery if they also take a 15-PGDH inhibitor.
- 2Semaglutide made muscle fibers 25–30% smaller after injury; adding the 15-PGDH inhibitor restored fiber size and boosted strength recovery by ~30%.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Proceedings of the National Academy of Sciences of the United States of America
Year
2026
Authors
Minas Nalbandian, Jameel Lone, Emmeran Le Moal, Ireh Kim, Kaitlin Jeuris, Y. Li, Peggy Kraft, Meng Zhao, K. Koleckar, Zeyuan Zhang, Katrin J. Svensson, Helen M. Blau
Related Content
Claims (10)
Blocking the enzyme 15-PGDH prevents the loss of skeletal muscle mass and strength in mice receiving semaglutide.
In obese mice receiving semaglutide, blocking the enzyme 15-PGDH with SW033291 increases muscle stem cell activity, restores muscle fiber size after injury, and improves muscle strength recovery without changing weight loss.
In obese mice, semaglutide treatment reduces gastrocnemius muscle mass by 15–20% while leaving maximal isometric muscle force unchanged during steady-state conditions.
In obese mice, semaglutide treatment results in muscle fibers that are 25–30% smaller during regeneration after injury compared to untreated mice, showing reduced muscle repair capacity.
In obese mice, semaglutide decreases abnormal calcium deposits in muscle tissue after injury but also reduces the growth of muscle fibers.
Blocking the enzyme 15-PGDH raises prostaglandin E2 levels in muscle stem cells of obese mice, and this elevation directly restores the cells' ability to multiply and mature, which semaglutide had suppressed.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.